Abdul-Ghani, Muhammad, Ralph A. DeFronzo, Stefano Del Prato, Robert Chilton, Rajvir Singh, and Robert E. J. Ryder. 2017. ‘Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?’ Diabetes Care 40(7):813–20. doi: 10.2337/dc16-2736.
Adamsson Eryd, S., A. M. Svensson, S. Franzén, B. Eliasson, P. M. Nilsson, and S. Gudbjörnsdottir. 2017. ‘Risk of Future Microvascular and Macrovascular Disease in People with Type 1 Diabetes of Very Long Duration: A National Study with 10-Year Follow-Up’. Diabetic Medicine 34(3):411–18. doi: 10.1111/dme.13266.
Andersson, Daniel P., Ylva Trolle Lagerros, Alessandra Grotta, Rino Bellocco, Mikael Lehtihet, and Martin J. Holzmann. 2017. ‘Association between Treatment for Erectile Dysfunction and Death or Cardiovascular Outcomes after Myocardial Infarction’. Heart. doi: 10.1136/heartjnl-2016-310746.
Anon. 1993. ‘The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus’. New England Journal of Medicine 329(14):977–86. doi: 10.1056/NEJM199309303291401.
Anon. 1998. ‘Effect of Intensive Blood-Glucose Control with Metformin on Complications in Overweight Patients with Type 2 Diabetes (UKPDS 34)’. The Lancet 352(9131):854–65. doi: 10.1016/S0140-6736(98)07037-8.
Anon. 2005a. ‘Effects of Different Blood Pressure–Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus’. Archives of Internal Medicine 165(12). doi: 10.1001/archinte.165.12.1410.
Anon. 2005b. ‘Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes’. New England Journal of Medicine 353(25):2643–53. doi: 10.1056/NEJMoa052187.
Anon. 2008a. ‘Effects of Intensive Glucose Lowering in Type 2 Diabetes’. New England Journal of Medicine 358(24):2545–59. doi: 10.1056/NEJMoa0802743.
Anon. 2008b. ‘Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes’. New England Journal of Medicine 358(24):2560–72. doi: 10.1056/NEJMoa0802987.
Anon. 2010a. ‘Diabetes Mellitus, Fasting Blood Glucose Concentration, and Risk of Vascular Disease: A Collaborative Meta-Analysis of 102 Prospective Studies’. The Lancet 375(9733):2215–22. doi: 10.1016/S0140-6736(10)60484-9.
Anon. 2010b. ‘Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus’. New England Journal of Medicine 362(17):1563–74. doi: 10.1056/NEJMoa1001282.
Anon. 2010c. ‘Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus’. New England Journal of Medicine 362(17):1575–85. doi: 10.1056/NEJMoa1001286.
Anon. 2010d. ‘Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus’. New England Journal of Medicine 362(17):1575–85. doi: 10.1056/NEJMoa1001286.
Anon. 2011a. ‘Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death’. New England Journal of Medicine 364(9):829–41. doi: 10.1056/NEJMoa1008862.
Anon. 2011b. ‘Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes’. New England Journal of Medicine 364(9):818–28. doi: 10.1056/NEJMoa1006524.
Anon. 2015a. International Textbook of Diabetes Mellitus. 4th ed. John Wiley & Sons, Incorporated.
Anon. 2015b. ‘Minimizing Hypoglycemia in Diabetes: Table 1’. Diabetes Care 38(8):1583–91. doi: 10.2337/dc15-0279.
Anon. 2017a. ‘Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes’. New England Journal of Medicine 376(16):1507–16. doi: 10.1056/NEJMoa1612836.
Anon. 2017b. ‘Microvascular Complications and Foot Care’. Diabetes Care 40(Supplement 1):S88–98. doi: 10.2337/dc17-S013.
Anon. 2017c. ‘Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes’. New England Journal of Medicine 377(3):300–301. doi: 10.1056/NEJMc1706292.
Anon. n.d.-a. ‘Assessing the Relationship between Admission Glucose Levels, Subsequent Length of Hospital Stay, Readmission and Mortality.’ Prime.
Anon. n.d.-b. ‘Cardiovascular Outcome Trials of Glucose-Lowering Drugs or Strategies in Type 2 Diabetes - ClinicalKey’. Retrieved (https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0140673614607947).
Anon. n.d.-c. ‘Diabetes Mellitus Type 2: A Driving Force for Urological Complications - ClinicalKey’. Retrieved (https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1043276016000321).
Anon. n.d.-d. ‘Diabetes Mellitus Type 2: A Driving Force for Urological Complications - ClinicalKey’. Retrieved (https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1043276016000321).
Anon. n.d.-e. ‘Diabetic Foot Problems: Prevention and Management  | Guidance and Guidelines | NICE’.
Anon. n.d.-f. ‘Effects of Reducing Blood Pressure on Renal Outcomes in Patients with Type 2 Diabetes: Focus on SGLT2 Inhibitors and EMPA-REG OUTCOME - ClinicalKey’.
Anon. n.d.-g. ‘Hypertension: Clinical Management of Primary Hypertension in Adults | NICE Guideline 127. August 2011’. Retrieved (http://www.nice.org.uk/guidance/cg127).
Anon. n.d.-h. ‘Integration of Recent Evidence into Management of Patients with Atherosclerotic Cardiovascular Disease and Type 2 Diabetes - ClinicalKey’.
Anon. n.d.-i. ‘Intensive Systolic Blood Pressure Control and Incident Chronic Kidney Disease in People with and without Diabetes Mellitus: Secondary Analyses of Two Randomised Controlled Trials- ClinicalKey’. Retrieved (https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300998).
Anon. n.d.-j. ‘Lipid-Lowering Efficacy of the PCSK9 Inhibitor Evolocumab (AMG 145) in Patients with Type 2 Diabetes: A Meta-Analysis of Individual Patient Data - ClinicalKey’. Retrieved (https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858716000036).
Anon. n.d.-k. ‘Macrovascular Disease and Risk Factors in Youth with Type 1 Diabetes: Time to Be More Attentive to Treatment?- ClinicalKey’. Retrieved (https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354).
Anon. n.d.-l. ‘Macrovascular Disease and Risk Factors in Youth with Type 1 Diabetes: Time to Be More Attentive to Treatment?- ClinicalKey’. Retrieved (https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354).
Anon. n.d.-m. ‘Macrovascular Disease and Risk Factors in Youth with Type 1 Diabetes: Time to Be More Attentive to Treatment?- ClinicalKey’. Retrieved (https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354).
Anon. n.d.-n. ‘Older Antidiabetic Drugs | The British Journal of Cardiology’. Retrieved (https://bjcardio.co.uk/2018/03/older-antidiabetic-drugs/).
Anon. n.d.-o. ‘Personalised Blood Pressure Ranges in Type 2 Diabetes?- ClinicalKey’. Retrieved (https://www.clinicalkey.com/#!/content/journal/1-s2.0-S2213858718300020).
Anon. n.d.-p. ‘Personalised Blood Pressure Ranges in Type 2 Diabetes?- ClinicalKey’. Retrieved (https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300020).
Anon. n.d.-q. ‘Personalised Treatment Targets in Type 2 Diabetes Patients: The Dutch Approach - ClinicalKey’. Retrieved (https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1751991816300626).
Anon. n.d.-r. ‘Proceedings of the 5th International DAWN Summit 2014: Acting Together to Make Person-Centred Diabetes Care a Reality - ClinicalKey’. Retrieved (https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0168822715001862).
Anon. n.d.-s. ‘The Changing Face of Diabetes Complications - ClinicalKey’. Retrieved (https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858716300109).
Anon. n.d.-t. ‘The Evolution of Diabetic Ketoacidosis: An Update of Its Etiology, Pathogenesis and Management - ClinicalKey’. Retrieved (https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S0026049515003728).
Anon. n.d.-u. ‘The Handbook for Vascular Risk Assessment, Risk Reduction and Risk Management - NHS Health Check’. Retrieved (http://www.healthcheck.nhs.uk/news/the_handbook_for_vascular_risk_assessment_risk_reduction_and_risk_management/).
Anon. n.d.-v. ‘Type 1 Diabetes in Adults: Diagnosis and Management | Guidance and Guidelines | NICE’.
Anon. n.d.-w. ‘Type 2 Diabetes in Adults: Management | Guidance and Guidelines | NICE’.
Atkinson, Mark A., George S. Eisenbarth, and Aaron W. Michels. 2014. ‘Type 1 Diabetes’. The Lancet 383(9911):69–82. doi: 10.1016/S0140-6736(13)60591-7.
Azmi, Shazli, Maryam Ferdousi, Uazman Alam, Ioannis N. Petropoulos, Georgios Ponirakis, Andrew Marshall, Omar Asghar, Hassan Fadavi, Wendy Jones, Mitra Tavakoli, Andrew J. M. Boulton, Maria Jeziorska, Handrean Soran, Nathan Efron, and Rayaz A. Malik. 2017. ‘Small-Fibre Neuropathy in Men with Type 1 Diabetes and Erectile Dysfunction: A Cross-Sectional Study’. Diabetologia. doi: 10.1007/s00125-017-4245-z.
Bangalore, S., S. Kumar, I. Lobach, and F. H. Messerli. 2011. ‘Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose: Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials’. Circulation 123(24):2799–2810. doi: 10.1161/CIRCULATIONAHA.110.016337.
Barzilay, J. I., B. R. Davis, S. L. Pressel, J. A. Cutler, P. T. Einhorn, H. R. Black, W. C. Cushman, C. E. Ford, K. L. Margolis, J. Moloo, S. Oparil, L. B. Piller, D. L. Simmons, M. E. Sweeney, P. K. Whelton, N. D. Wong, and J. T. Wright. 2012. ‘Long-Term Effects of Incident Diabetes Mellitus on Cardiovascular Outcomes in People Treated for Hypertension: The ALLHAT Diabetes Extension Study’. Circulation: Cardiovascular Quality and Outcomes 5(2):153–62. doi: 10.1161/CIRCOUTCOMES.111.962522.
Bianchi, Cristina, Roberto Miccoli, and Stefano Del Prato. 2013a. ‘Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction?’ Current Diabetes Reports 13(3):403–10. doi: 10.1007/s11892-013-0371-2.
Bianchi, Cristina, Roberto Miccoli, and Stefano Del Prato. 2013b. ‘Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction?’ Current Diabetes Reports 13(3):403–10. doi: 10.1007/s11892-013-0371-2.
Black, J. A., S. J. Sharp, N. J. Wareham, A. Sandbaek, G. E. Rutten, T. Lauritzen, K. Khunti, M. J. Davies, K. Borch-Johnsen, S. J. Griffin, and R. K. Simmons. 2014. ‘Change in Cardiovascular Risk Factors Following Early Diagnosis of Type 2 Diabetes: A Cohort Analysis of a Cluster-Randomised Trial’. British Journal of General Practice 64(621):e208–16. doi: 10.3399/bjgp14X677833.
Boulton, Andrew JM, William J. Jeffcoate, Teresa LZ Jones, and Jan S. Ulbrecht. 2009. ‘International Collaborative Research on Charcot’s Disease - 2009’. The Lancet 373(9658):105–6. doi: 10.1016/S0140-6736(09)60019-2.
Boussageon, R., T. Bejan-Angoulvant, M. Saadatian-Elahi, S. Lafont, C. Bergeonneau, B. Kassai, S. Erpeldinger, J. M. Wright, F. Gueyffier, and C. Cornu. 2011. ‘Effect of Intensive Glucose Lowering Treatment on All Cause Mortality, Cardiovascular Death, and Microvascular Events in Type 2 Diabetes: Meta-Analysis of Randomised Controlled Trials’. BMJ 343(jul26 1):d4169–d4169. doi: 10.1136/bmj.d4169.
Braffett, Barbara H., Hunter Wessells, and Aruna V. Sarma. 2016. ‘Urogenital Autonomic Dysfunction in Diabetes’. Current Diabetes Reports 16(12). doi: 10.1007/s11892-016-0824-5.
Çakici, N., T. M. Fakkel, J. W. van Neck, A. P. Verhagen, and J. H. Coert. 2016a. ‘Systematic Review of Treatments for Diabetic Peripheral Neuropathy’. Diabetic Medicine 33(11):1466–76. doi: 10.1111/dme.13083.
Çakici, N., T. M. Fakkel, J. W. van Neck, A. P. Verhagen, and J. H. Coert. 2016b. ‘Systematic Review of Treatments for Diabetic Peripheral Neuropathy’. Diabetic Medicine 33(11):1466–76. doi: 10.1111/dme.13083.
Cefalu, William T., Julio Rosenstock, Derek LeRoith, Lawrence Blonde, and Matthew C. Riddle. 2016. ‘Getting to the "Heart” of the Matter on Diabetic Cardiovascular Disease: "Thanks for the Memory”’. Diabetes Care 39(5):664–67. doi: 10.2337/dc16-0405.
Chatterjee, Sudesna, Kamlesh Khunti, and Melanie J. Davies. 2017. ‘Type 2 Diabetes’. The Lancet. doi: 10.1016/S0140-6736(17)30058-2.
Cheung, Ning, Paul Mitchell, and Tien Yin Wong. 2010. ‘Diabetic Retinopathy’. The Lancet 376(9735):124–36. doi: 10.1016/S0140-6736(09)62124-3.
Chloe L. Edridge. 2015. ‘Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and Meta-Analysis of Population Based Studies’. PLoS ONE 10(6). doi: doi:  10.1371/journal.pone.0126427.
Clokie, M., A. L. Greenway, K. Harding, N. J. Jones, K. Vedhara, F. Game, and K. K. Dhatariya. 2017. ‘New Horizons in the Understanding of the Causes and Management of Diabetic Foot Disease: Report from the 2017 Diabetes UK Annual Professional Conference Symposium’. Diabetic Medicine 34(3):305–15. doi: 10.1111/dme.13313.
Dahlöf, Björn, Peter S. Sever, Neil R. Poulter, Hans Wedel, D. Gareth Beevers, Mark Caulfield, Rory Collins, Sverre E. Kjeldsen, Arni Kristinsson, Gordon T. McInnes, Jesper Mehlsen, Markku Nieminen, Eoin O’Brien, and Jan Östergren. 2005. ‘Prevention of Cardiovascular Events with an Antihypertensive Regimen of Amlodipine Adding Perindopril as Required versus Atenolol Adding Bendroflumethiazide as Required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A Multicentre Randomised Controlled Trial’. The Lancet 366(9489):895–906. doi: 10.1016/S0140-6736(05)67185-1.
Dana Dabelea. n.d. ‘Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood’. JAMA 317(8):825–35. doi: 10.1001/jama.2017.0686.
Denig, P., J. Schuling, F. Haaijer-Ruskamp, and J. Voorham. 2014. ‘Effects of a Patient Oriented Decision Aid for Prioritising Treatment Goals in Diabetes: Pragmatic Randomised Controlled Trial’. BMJ 349(sep25 6):g5651–g5651. doi: 10.1136/bmj.g5651.
Dhatariya, K., N. Levy, A. Kilvert, B. Watson, D. Cousins, D. Flanagan, L. Hilton, C. Jairam, K. Leyden, A. Lipp, D. Lobo, M. Sinclair-Hammersley, and G. Rayman. 2012. ‘NHS Diabetes Guideline for the Perioperative Management of the Adult Patient with Diabetes’. Diabetic Medicine 29(4):420–33. doi: 10.1111/j.1464-5491.2012.03582.x.
Dhatariya, Ketan K., and Priyathama Vellanki. 2017. ‘Treatment of Diabetic Ketoacidosis (DKA)/Hyperglycemic Hyperosmolar State (HHS): Novel Advances in the Management of Hyperglycemic Crises (UK Versus USA)’. Current Diabetes Reports 17(5). doi: 10.1007/s11892-017-0857-4.
Duckworth, William, Carlos Abraira, Thomas Moritz, Domenic Reda, Nicholas Emanuele, Peter D. Reaven, Franklin J. Zieve, Jennifer Marks, Stephen N. Davis, Rodney Hayward, Stuart R. Warren, Steven Goldman, Madeline McCarren, Mary Ellen Vitek, William G. Henderson, and Grant D. Huang. 2009. ‘Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes’. New England Journal of Medicine 360(2):129–39. doi: 10.1056/NEJMoa0808431.
Dwamena, Francesca, Margaret Holmes-Rovner, Carolyn M. Gaulden, Sarah Jorgenson, Gelareh Sadigh, Alla Sikorskii, Simon Lewin, Robert C. Smith, John Coffey, Adesuwa Olomu, and Michael Beasley. 1996. ‘Interventions for Providers to Promote a Patient-Centred Approach in Clinical Consultations’. in Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd.
Ele Ferrannini. 2015. ‘Impact of Glucose-Lowering Drugs on Cardiovascular Disease in Type 2 Diabetes’. European Heart Journal 36(34):2288–96.
Elliott, William J., and Peter M. Meyer. 2007. ‘Incident Diabetes in Clinical Trials of Antihypertensive Drugs: A Network Meta-Analysis’. The Lancet 369(9557):201–7. doi: 10.1016/S0140-6736(07)60108-1.
Ferrannini, Ele, and William C. Cushman. 2012. ‘Diabetes and Hypertension: The Bad Companions’. The Lancet 380(9841):601–10. doi: 10.1016/S0140-6736(12)60987-8.
Filippatos, Theodosios, Vasilios Tsimihodimos, Eleni Pappa, and Moses Elisaf. 2017. ‘Pathophysiology of Diabetic Dyslipidaemia’. Current Vascular Pharmacology 15(999):1–1.
Fisher, L., J. S. Gonzalez, and W. H. Polonsky. 2014. ‘The Confusing Tale of Depression and Distress in Patients with Diabetes: A Call for Greater Clarity and Precision’. Diabetic Medicine 31(7):764–72. doi: 10.1111/dme.12428.
Foresta, C., A. Ferlin, A. Lenzi, and P. Montorsi. 2017. ‘The Great Opportunity of the Andrological Patient: Cardiovascular and Metabolic Risk Assessment and Prevention’. Andrology. doi: 10.1111/andr.12342.
Fox, Caroline S., Sherita Hill Golden, Cheryl Anderson, George A. Bray, Lora E. Burke, Ian H. de Boer, Prakash Deedwania, Robert H. Eckel, Abby G. Ershow, Judith Fradkin, Silvio E. Inzucchi, Mikhail Kosiborod, Robert G. Nelson, Mahesh J. Patel, Michael Pignone, Laurie Quinn, Philip R. Schauer, Elizabeth Selvin, and Dorothea K. Vafiadis. 2015. ‘Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association’. Diabetes Care 38(9):1777–1803. doi: 10.2337/dci15-0012.
Gæde, Peter, Henrik Lund-Andersen, Hans-Henrik Parving, and Oluf Pedersen. 2008. ‘Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes’. New England Journal of Medicine 358(6):580–91. doi: 10.1056/NEJMoa0706245.
Gæde, Peter, Jens Oellgaard, Bendix Carstensen, Peter Rossing, Henrik Lund-Andersen, Hans-Henrik Parving, and Oluf Pedersen. 2016. ‘Years of Life Gained by Multifactorial Intervention in Patients with Type 2 Diabetes Mellitus and Microalbuminuria: 21 Years Follow-up on the Steno-2 Randomised Trial’. Diabetologia 59(11):2298–2307. doi: 10.1007/s00125-016-4065-6.
Game, Frances. 2016. ‘Classification of Diabetic Foot Ulcers’. Diabetes/Metabolism Research and Reviews 32:186–94. doi: 10.1002/dmrr.2746.
Giorgino, Francesco, Philip D. Home, and Jaakko Tuomilehto. 2016. ‘Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?’ Diabetes Care 39(Supplement 2):S187–95. doi: 10.2337/dcS15-3023.
Giovanni Corona. 2016. ‘Sexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over Time and Drug and Non-Drug Correlated Factors’. PLoS ONE 11(10). doi: doi:  10.1371/journal.pone.0157915.
Hayward, Rodney A., Peter D. Reaven, Wyndy L. Wiitala, Gideon D. Bahn, Domenic J. Reda, Ling Ge, Madeline McCarren, William C. Duckworth, and Nicholas V. Emanuele. 2015a. ‘Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes’. New England Journal of Medicine 372(23):2197–2206. doi: 10.1056/NEJMoa1414266.
Hayward, Rodney A., Peter D. Reaven, Wyndy L. Wiitala, Gideon D. Bahn, Domenic J. Reda, Ling Ge, Madeline McCarren, William C. Duckworth, and Nicholas V. Emanuele. 2015b. ‘Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes’. New England Journal of Medicine 372(23):2197–2206. doi: 10.1056/NEJMoa1414266.
Holman, Rury R., M. Angelyn Bethel, Robert J. Mentz, Vivian P. Thompson, Yuliya Lokhnygina, John B. Buse, Juliana C. Chan, Jasmine Choi, Stephanie M. Gustavson, Nayyar Iqbal, Aldo P. Maggioni, Steven P. Marso, Peter Öhman, Neha J. Pagidipati, Neil Poulter, Ambady Ramachandran, Bernard Zinman, and Adrian F. Hernandez. 2017. ‘Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes’. New England Journal of Medicine 377(13):1228–39. doi: 10.1056/NEJMoa1612917.
Holman, Rury R., Sanjoy K. Paul, M. Angelyn Bethel, David R. Matthews, and H. Andrew W. Neil. 2008. ‘10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes’. New England Journal of Medicine 359(15):1577–89. doi: 10.1056/NEJMoa0806470.
Holt, R. I. G. 2017. ‘Understanding of the Causes and Management of Diabetic Foot Disease’. Diabetic Medicine 34(3):303–4. doi: 10.1111/dme.13319.
Holt, Richard I. G. 2010. Textbook of Diabetes. 4th ed. Chichester: Wiley-Blackwell.
Holt, Richard I. G., Clive Cockram, Allan Flyvbjerg, and Barry J. Goldstein. 2016. Textbook of Diabetes. 5th ed. Somerset: John Wiley & Sons, Incorporated.
Holt, Richard I. G., Clive S. Cockram, Allan Flyvbjerg, and Barry J. Goldstein, eds. 2017. Textbook of Diabetes. Fifth edition. Chichester, West Sussex, UK: Wiley Blackwell.
Hotaling, James M., Aruna V. Sarma, Darshan P. Patel, Barbara H. Braffett, Patricia A. Cleary, Eva Feldman, William H. Herman, Catherine L. Martin, Alan M. Jacobson, Hunter Wessells, and Rodica Pop-Busui. 2016a. ‘Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes’. Diabetes Care 39(9):1587–93. doi: 10.2337/dc16-0059.
Hotaling, James M., Aruna V. Sarma, Darshan P. Patel, Barbara H. Braffett, Patricia A. Cleary, Eva Feldman, William H. Herman, Catherine L. Martin, Alan M. Jacobson, Hunter Wessells, and Rodica Pop-Busui. 2016b. ‘Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes’. Diabetes Care 39(9):1587–93. doi: 10.2337/dc16-0059.
Ian Blumer, MD, FRCPC1, 2, Maureen Clement, MD, CCFP3, ,. n.d. ‘Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges’. Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges.
Jhamb, Shaurya, Venkat N. Vangaveti, and Usman H. Malabu. 2016. ‘Genetic and Molecular Basis of Diabetic Foot Ulcers: Clinical Review’. Journal of Tissue Viability 25(4):229–36. doi: 10.1016/j.jtv.2016.06.005.
Jin, Dong-mei, Yun Xu, Deng-feng Geng, and Tie-bin Yan. 2010. ‘Effect of Transcutaneous Electrical Nerve Stimulation on Symptomatic Diabetic Peripheral Neuropathy: A Meta-Analysis of Randomized Controlled Trials’. Diabetes Research and Clinical Practice 89(1):10–15. doi: 10.1016/j.diabres.2010.03.021.
Johal, S., F. Jackson-Spence, H. Gillott, S. Tahir, J. Mytton, F. Evison, B. Stephenson, J. Nath, and A. Sharif. 2017. ‘Pre-Existing Diabetes Is a Risk Factor for Increased Rates of Cellular Rejection after Kidney Transplantation: An Observational Cohort Study’. Diabetic Medicine. doi: 10.1111/dme.13383.
Kaul, Sanjay. 2017. ‘Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials’. Diabetes Care 40(7):821–31. doi: 10.2337/dc17-0291.
Khunti, K., M. L. Wolden, B. L. Thorsted, M. Andersen, and M. J. Davies. 2013. ‘Clinical Inertia in People With Type 2 Diabetes: A Retrospective Cohort Study of More than 80,000 People’. Diabetes Care 36(11):3411–17. doi: 10.2337/dc13-0331.
Khunti, Kamlesh, Melanie Davies, Azeem Majeed, Brian Larsen Thorsted, Michael Lyng Wolden, and Sanjoy K. Paul. 2015a. ‘Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study’. Diabetes Care 38(2):316–22. doi: 10.2337/dc14-0920.
Khunti, Kamlesh, Melanie Davies, Azeem Majeed, Brian Larsen Thorsted, Michael Lyng Wolden, and Sanjoy K. Paul. 2015b. ‘Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study’. Diabetes Care 38(2):316–22. doi: 10.2337/dc14-0920.
Koye, D. N., J. E. Shaw, C. M. Reid, R. C. Atkins, A. T. Reutens, and D. J. Magliano. 2017. ‘Incidence of Chronic Kidney Disease among People with Diabetes: A Systematic Review of Observational Studies’. Diabetic Medicine. doi: 10.1111/dme.13324.
Kunutsor, S. K., S. Seidu, and K. Khunti. 2017. ‘Aspirin for Primary Prevention of Cardiovascular and All-Cause Mortality Events in Diabetes: Updated Meta-Analysis of Randomized Controlled Trials’. Diabetic Medicine 34(3):316–27. doi: 10.1111/dme.13133.
Liew, G., P. Mitchell, and T. Y. Wong. 2009. ‘Systemic Management of Diabetic Retinopathy’. BMJ 338(feb12 1):b441–b441. doi: 10.1136/bmj.b441.
Lindholm, Lars H., Hans Ibsen, Björn Dahlöf, Richard B. Devereux, Gareth Beevers, Ulf de Faire, Frej Fyhrquist, Stevo Julius, Sverre E. Kjeldsen, Krister Kristiansson, Ole Lederballe-Pedersen, Markku S. Nieminen, Per Omvik, Suzanne Oparil, Hans Wedel, Peter Aurup, Jonathan Edelman, and Steven Snapinn. 2002. ‘Cardiovascular Morbidity and Mortality in Patients with Diabetes in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial against Atenolol’. The Lancet 359(9311):1004–10. doi: 10.1016/S0140-6736(02)08090-X.
Malavige, Lasantha S., Pabasi Wijesekara, Priyanga Ranasinghe, and Jonathan C. Levy. 2015. ‘The Association between Physical Activity and Sexual Dysfunction in Patients with Diabetes Mellitus of European and South Asian Origin: The Oxford Sexual Dysfunction Study’. European Journal of Medical Research 20(1). doi: 10.1186/s40001-015-0186-5.
Marso, Steven P., Gilbert H. Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F. E. Mann, Michael A. Nauck, Steven E. Nissen, Stuart Pocock, Neil R. Poulter, Lasse S. Ravn, William M. Steinberg, Mette Stockner, Bernard Zinman, Richard M. Bergenstal, and John B. Buse. 2016. ‘Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes’. New England Journal of Medicine 375(4):311–22. doi: 10.1056/NEJMoa1603827.
Matheus, Alessandra Saldanha de Mattos, Lucianne Righeti Monteiro Tannus, Roberta Arnoldi Cobas, Catia C. Sousa Palma, Carlos Antonio Negrato, and Marilia de Brito Gomes. 2013. ‘Impact of Diabetes on Cardiovascular Disease: An Update’. International Journal of Hypertension 2013:1–15. doi: 10.1155/2013/653789.
Mayer-Davis, Elizabeth J., Jean M. Lawrence, Dana Dabelea, Jasmin Divers, Scott Isom, Lawrence Dolan, Giuseppina Imperatore, Barbara Linder, Santica Marcovina, David J. Pettitt, Catherine Pihoker, Sharon Saydah, and Lynne Wagenknecht. 2017. ‘Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012’. New England Journal of Medicine 376(15):1419–29. doi: 10.1056/NEJMoa1610187.
Melanie Davies. 2016. ‘The Treatment of Type 2 Diabetes in the Presence of Renal Impairment: What We Should Know about Newer Therapies’. Clinical Pharmacology : Advances and Applications 8. doi: doi:  10.2147/CPAA.S82008.
Micha, Renata, Jose L. Peñalvo, Frederick Cudhea, Fumiaki Imamura, Colin D. Rehm, and Dariush Mozaffarian. 2017. ‘Association Between Dietary Factors and Mortality From Heart Disease, Stroke, and Type 2 Diabetes in the United States’. JAMA 317(9). doi: 10.1001/jama.2017.0947.
Miller, M. E., D. E. Bonds, H. C. Gerstein, E. R. Seaquist, R. M. Bergenstal, J. Calles-Escandon, R. D. Childress, T. E. Craven, R. M. Cuddihy, G. Dailey, M. N. Feinglos, F. Ismail-Beigi, J. F. Largay, P. J. O’Connor, T. Paul, P. J. Savage, U. K. Schubart, A. Sood, and S. Genuth. 2010. ‘The Effects of Baseline Characteristics, Glycaemia Treatment Approach, and Glycated Haemoglobin Concentration on the Risk of Severe Hypoglycaemia: Post Hoc Epidemiological Analysis of the ACCORD Study’. BMJ 340(jan08 1):b5444–b5444. doi: 10.1136/bmj.b5444.
Moreton, R. B. R., I. M. Stratton, S. J. Chave, H. Lipinski, and P. H. Scanlon. 2017. ‘Factors Determining Uptake of Diabetic Retinopathy Screening in Oxfordshire’. Diabetic Medicine 34(7):993–99. doi: 10.1111/dme.13350.
Navaneethan, Sankar D., Jesse D. Schold, Stacey E. Jolly, Susana Arrigain, Wolfgang C. Winkelmayer, and Joseph V. Nally. 2017. ‘Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD’. American Journal of Kidney Diseases. doi: 10.1053/j.ajkd.2016.11.018.
Nicolucci, A., and E. Standl. 2011. ‘Antiplatelet Therapy for Every Diabetic Person?’ Diabetes Care 34(Supplement_2):S150–54. doi: 10.2337/dc11-s210.
Omland, Torbjørn, Anna Randby, Harald Hrubos-Strøm, Helge Røsjø, and Gunnar Einvik. 2016. ‘Relation of Erectile Dysfunction to Subclinical Myocardial Injury’. The American Journal of Cardiology 118(12):1821–25. doi: 10.1016/j.amjcard.2016.08.070.
Orchard, Trevor J., David M. Nathan, Bernard Zinman, Patricia Cleary, David Brillon, Jye-Yu C. Backlund, and John M. Lachin. 2015. ‘Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-Term Mortality’. JAMA 313(1). doi: 10.1001/jama.2014.16107.
P Naidoo. 2015. ‘Lower Limb Complications of Diabetes Mellitus: A Comprehensive Review with Clinicopathological Insights from a Dedicated High-Risk Diabetic Foot Multidisciplinary Team’. The British Journal of Radiology 88(1053). doi: doi:  10.1259/bjr.20150135.
Paul, Sanjoy K., Kerenaftali Klein, Brian L. Thorsted, Michael L. Wolden, and Kamlesh Khunti. 2015. ‘Delay in Treatment Intensification Increases the Risks of Cardiovascular Events in Patients with Type 2 Diabetes’. Cardiovascular Diabetology 14(1). doi: 10.1186/s12933-015-0260-x.
Pickering, Raelene J., Carlos J. Rosado, Arpeeta Sharma, Shareefa Buksh, Mitchel Tate, and Judy B. de Haan. 2018. ‘Recent Novel Approaches to Limit Oxidative Stress and Inflammation in Diabetic Complications’. Clinical & Translational Immunology 7(4). doi: 10.1002/cti2.1016.
Piepoli, Massimo F., Arno W. Hoes, Stefan Agewall, Christian Albus, Carlos Brotons, Alberico L. Catapano, Marie-Therese Cooney, Ugo Corrà, Bernard Cosyns, Christi Deaton, Ian Graham, Michael Stephen Hall, F. D. Richard Hobbs, Maja-Lisa Løchen, Herbert Löllgen, Pedro Marques-Vidal, Joep Perk, Eva Prescott, Josep Redon, Dimitrios J. Richter, Naveed Sattar, Yvo Smulders, Monica Tiberi, H. Bart van der Worp, Ineke van Dis, and W. M. Monique Verschuren. 2016. ‘2016 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice’. Atherosclerosis 252:207–74. doi: 10.1016/j.atherosclerosis.2016.05.037.
Rawshani, Aidin, Araz Rawshani, Stefan Franzén, Björn Eliasson, Ann-Marie Svensson, Mervete Miftaraj, Darren K. McGuire, Naveed Sattar, Annika Rosengren, and Soffia Gudbjörnsdottir. 2017a. ‘Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes’. New England Journal of Medicine 376(15):1407–18. doi: 10.1056/NEJMoa1608664.
Rawshani, Aidin, Araz Rawshani, Stefan Franzén, Björn Eliasson, Ann-Marie Svensson, Mervete Miftaraj, Darren K. McGuire, Naveed Sattar, Annika Rosengren, and Soffia Gudbjörnsdottir. 2017b. ‘Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes’. New England Journal of Medicine 376(15):1407–18. doi: 10.1056/NEJMoa1608664.
Ray, Kausik K., Sreenivasa Rao Kondapally Seshasai, Shanelle Wijesuriya, Rupa Sivakumaran, Sarah Nethercott, David Preiss, Sebhat Erqou, and Naveed Sattar. 2009. ‘Effect of Intensive Control of Glucose on Cardiovascular Outcomes and Death in Patients with Diabetes Mellitus: A Meta-Analysis of Randomised Controlled Trials’. The Lancet 373(9677):1765–72. doi: 10.1016/S0140-6736(09)60697-8.
Richard W. Nesto. 2008. ‘LDL Cholesterol Lowering in Type 2 Diabetes: What Is the Optimum Approach?’ Clinical Diabetes 26(1).
Ritholz, M. D., T. MacNeil, and K. Weinger. 2017a. ‘Difficult Conversations: Adults with Diabetes and the Discussion of Microvascular Complications’. Diabetic Medicine. doi: 10.1111/dme.13419.
Ritholz, M. D., T. MacNeil, and K. Weinger. 2017b. ‘Difficult Conversations: Adults with Diabetes and the Discussion of Microvascular Complications’. Diabetic Medicine 34(10):1447–55. doi: 10.1111/dme.13419.
Romero-Aroca, Pedro, Raul Navarro-Gil, Aida Valls-Mateu, Ramon Sagarra-Alamo, Antonio Moreno-Ribas, and Nuria Soler. 2017a. ‘Differences in Incidence of Diabetic Retinopathy between Type 1 and 2 Diabetes Mellitus: A Nine-Year Follow-up Study’. British Journal of Ophthalmology. doi: 10.1136/bjophthalmol-2016-310063.
Romero-Aroca, Pedro, Raul Navarro-Gil, Aida Valls-Mateu, Ramon Sagarra-Alamo, Antonio Moreno-Ribas, and Nuria Soler. 2017b. ‘Differences in Incidence of Diabetic Retinopathy between Type 1 and 2 Diabetes Mellitus: A Nine-Year Follow-up Study’. British Journal of Ophthalmology. doi: 10.1136/bjophthalmol-2016-310063.
Romero-Aroca, Pedro, Raul Navarro-Gil, Aida Valls-Mateu, Ramon Sagarra-Alamo, Antonio Moreno-Ribas, and Nuria Soler. 2017c. ‘Differences in Incidence of Diabetic Retinopathy between Type 1 and 2 Diabetes Mellitus: A Nine-Year Follow-up Study’. British Journal of Ophthalmology. doi: 10.1136/bjophthalmol-2016-310063.
Rosenberg, Jamie B., and Irena Tsui. 2017. ‘Screening for Diabetic Retinopathy’. New England Journal of Medicine 376(16):1587–88. doi: 10.1056/NEJMe1701820.
Saha, Sandeep A., and Rohit R. Arora. 2010. ‘Fibrates in the Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus – A Pooled Meta-Analysis of Randomized Placebo-Controlled Clinical Trials’. International Journal of Cardiology 141(2):157–66. doi: 10.1016/j.ijcard.2008.11.211.
Santi, Daniele, Antonio R. M. Granata, Alessandro Guidi, Elisa Pignatti, Tommaso Trenti, Laura Roli, Roberto Bozic, Stefano Zaza, Chiara Pacchioni, Stefania Romano, Jerzy Roch Nofer, Vincenzo Rochira, Cesare Carani, and Manuela Simoni. 2016. ‘Six Months of Daily Treatment with Vardenafil Improves Parameters of Endothelial Inflammation and of Hypogonadism in Male Patients with Type 2 Diabetes and Erectile Dysfunction: A Randomized, Double-Blind, Prospective Trial’. European Journal of Endocrinology 174(4):513–22. doi: 10.1530/EJE-15-1100.
Schrier, R. W., R. O. Estacio, and B. Jeffers. 1996. ‘Appropriate Blood Pressure Control in NIDDM (ABCD) Trial’. Diabetologia 39(12):1646–54. doi: 10.1007/s001250050629.
Scott, A. R. 2015. ‘Management of Hyperosmolar Hyperglycaemic State in Adults with Diabetes’. Diabetic Medicine 32(6):714–24. doi: 10.1111/dme.12757.
Seidu, S., F. A. Achana, L. J. Gray, M. J. Davies, and K. Khunti. 2016. ‘Effects of Glucose-Lowering and Multifactorial Interventions on Cardiovascular and Mortality Outcomes: A Meta-Analysis of Randomized Control Trials’. Diabetic Medicine 33(3):280–89. doi: 10.1111/dme.12885.
Soliman, Elsayed Z., Jye-Yu C. Backlund, Ionut Bebu, Trevor J. Orchard, Bernard Zinman, and John M. Lachin. 2017. ‘Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study’. Diabetes Care 40(6):793–99. doi: 10.2337/dc16-2050.
Solomon, Sharon D., Emily Chew, Elia J. Duh, Lucia Sobrin, Jennifer K. Sun, Brian L. VanderBeek, Charles C. Wykoff, and Thomas W. Gardner. 2017a. ‘Diabetic Retinopathy: A Position Statement by the American Diabetes Association’. Diabetes Care 40(3):412–18. doi: 10.2337/dc16-2641.
Solomon, Sharon D., Emily Chew, Elia J. Duh, Lucia Sobrin, Jennifer K. Sun, Brian L. VanderBeek, Charles C. Wykoff, and Thomas W. Gardner. 2017b. ‘Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418’. Diabetes Care 40(6):809.3-809. doi: 10.2337/dc17-er06e.
Solomon, Sharon D., Emily Chew, Elia J. Duh, Lucia Sobrin, Jennifer K. Sun, Brian L. VanderBeek, Charles C. Wykoff, and Thomas W. Gardner. 2017c. ‘Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418’. Diabetes Care. doi: 10.2337/dc17-er06e.
Solomon, Sharon D., Emily Chew, Elia J. Duh, Lucia Sobrin, Jennifer K. Sun, Brian L. VanderBeek, Charles C. Wykoff, and Thomas W. Gardner. 2017d. ‘Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418’. Diabetes Care. doi: 10.2337/dc17-er06e.
Sultan, A., F. Perriard, V. Macioce, D. Mariano-Goulart, C. Boegner, J. P. Daures, and A. Avignon. 2017a. ‘Evolution of Silent Myocardial Ischaemia Prevalence and Cardiovascular Disease Risk Factor Management in Type 2 Diabetes over a 10-Year Period: An Observational Study’. Diabetic Medicine. doi: 10.1111/dme.13364.
Sultan, A., F. Perriard, V. Macioce, D. Mariano-Goulart, C. Boegner, J. P. Daures, and A. Avignon. 2017b. ‘Evolution of Silent Myocardial Ischaemia Prevalence and Cardiovascular Disease Risk Factor Management in Type 2 Diabetes over a 10-Year Period: An Observational Study’. Diabetic Medicine. doi: 10.1111/dme.13364.
Turnbull, F. M., C. Abraira, R. J. Anderson, R. P. Byington, J. P. Chalmers, W. C. Duckworth, G. W. Evans, H. C. Gerstein, R. R. Holman, T. E. Moritz, B. C. Neal, T. Ninomiya, A. A. Patel, S. K. Paul, F. Travert, and M. Woodward. 2009a. ‘Intensive Glucose Control and Macrovascular Outcomes in Type 2 Diabetes’. Diabetologia 52(11):2288–98. doi: 10.1007/s00125-009-1470-0.
Turnbull, F. M., C. Abraira, R. J. Anderson, R. P. Byington, J. P. Chalmers, W. C. Duckworth, G. W. Evans, H. C. Gerstein, R. R. Holman, T. E. Moritz, B. C. Neal, T. Ninomiya, A. A. Patel, S. K. Paul, F. Travert, and M. Woodward. 2009b. ‘Intensive Glucose Control and Macrovascular Outcomes in Type 2 Diabetes’. Diabetologia 52(11):2288–98. doi: 10.1007/s00125-009-1470-0.
UK Prospective Diabetes Study Group. 1998. ‘Tight Blood Pressure Control and Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 38’. BMJ : British Medical Journal 317(7160).
Umpierrez, Guillermo, and Mary Korytkowski. 2016a. ‘Diabetic Emergencies — Ketoacidosis, Hyperglycaemic Hyperosmolar State and Hypoglycaemia’. Nature Reviews Endocrinology 12(4):222–32. doi: 10.1038/nrendo.2016.15.
Umpierrez, Guillermo, and Mary Korytkowski. 2016b. ‘Diabetic Emergencies — Ketoacidosis, Hyperglycaemic Hyperosmolar State and Hypoglycaemia’. Nature Reviews Endocrinology 12(4):222–32. doi: 10.1038/nrendo.2016.15.
Valencia, Willy Marcos, and Hermes Florez. 2017. ‘How to Prevent the Microvascular Complications of Type 2 Diabetes beyond Glucose Control’. BMJ. doi: 10.1136/bmj.i6505.
Wannamethee, S. Goya, A. Gerald Shaper, Peter H. Whincup, Lucy Lennon, and Naveed Sattar. 2011. ‘Impact of Diabetes on Cardiovascular Disease Risk and All-Cause Mortality in Older Men: Influence of Age at Onset, Diabetes Duration and Established and Novel Rosk Factors’. Archives of Internal Medicine 171(5). doi: 10.1001/archinternmed.2011.2.
Webb, D. R., F. Zaccardi, M. J. Davies, S. J. Griffin, N. J. Wareham, R. K. Simmons, G. E. Rutten, A. Sandbaek, T. Lauritzen, K. Borch-Johnsen, and K. Khunti. 2016. ‘Cardiovascular Risk Factors and Incident Albuminuria in Screen-Detected Type 2 Diabetes’. Diabetes/Metabolism Research and Reviews. doi: 10.1002/dmrr.2877.
Weber, Michael A., George L. Bakris, Kenneth Jamerson, Matthew Weir, Sverre E. Kjeldsen, Richard B. Devereux, Eric J. Velazquez, Björn Dahlöf, Roxzana Y. Kelly, Tsushung A. Hua, Allen Hester, and Bertram Pitt. 2010. ‘Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes’. Journal of the American College of Cardiology 56(1):77–85. doi: 10.1016/j.jacc.2010.02.046.
Whelton, Paul K. 2005. ‘Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia’. Archives of Internal Medicine 165(12). doi: 10.1001/archinte.165.12.1401.
White, Jon, Daniel I. Swerdlow, David Preiss, Zammy Fairhurst-Hunter, Brendan J. Keating, Folkert W. Asselbergs, Naveed Sattar, Steve E. Humphries, Aroon D. Hingorani, and Michael V. Holmes. 2016. ‘Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes’. JAMA Cardiology 1(6). doi: 10.1001/jamacardio.2016.1884.
Wong, Muh Geot, Vlado Perkovic, John Chalmers, Mark Woodward, Qiang Li, Mark E. Cooper, Pavel Hamet, Stephen Harrap, Simon Heller, Stephen MacMahon, Giuseppe Mancia, Michel Marre, David Matthews, Bruce Neal, Neil Poulter, Anthony Rodgers, Bryan Williams, and Sophia Zoungas. 2016a. ‘Long-Term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON’. Diabetes Care 39(5):694–700. doi: 10.2337/dc15-2322.
Wong, Muh Geot, Vlado Perkovic, John Chalmers, Mark Woodward, Qiang Li, Mark E. Cooper, Pavel Hamet, Stephen Harrap, Simon Heller, Stephen MacMahon, Giuseppe Mancia, Michel Marre, David Matthews, Bruce Neal, Neil Poulter, Anthony Rodgers, Bryan Williams, and Sophia Zoungas. 2016b. ‘Long-Term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON’. Diabetes Care 39(5):694–700. doi: 10.2337/dc15-2322.
Yavuz, Metin, Ali Ersen, Jessica Hartos, Brandy Schwarz, Alan G. Garrett, Lawrence A. Lavery, Dane K. Wukich, and Linda S. Adams. 2017. ‘Plantar Shear Stress in Individuals With a History of Diabetic Foot Ulcer: An Emerging Predictive Marker for Foot Ulceration’. Diabetes Care 40(2):e14–15. doi: 10.2337/dc16-2204.
Yudkin, John S., Bernd Richter, and Edwin AM Gale. 2011. ‘Intensified Glucose Control in Type 2 Diabetes—Whose Agenda?’ The Lancet 377(9773):1220–22. doi: 10.1016/S0140-6736(10)61112-9.
Zaccardi, Francesco, David R. Webb, Melanie J. Davies, Nafeesa N. Dhalwani, Laura J. Gray, Sudesna Chatterjee, Gemma Housley, Dominick Shaw, James W. Hatton, and Kamlesh Khunti. 2017. ‘Predicting Hospital Stay, Mortality and Readmission in People Admitted for Hypoglycaemia: Prognostic Models Derivation and Validation’. Diabetologia. doi: 10.1007/s00125-017-4235-1.
Zaccardi, Francesco, David R. Webb, Melanie J. Davies, Nafeesa N. Dhalwani, Gemma Housley, Dominic Shaw, James W. Hatton, and Kamlesh Khunti. 2017. ‘Risk Factors and Outcome Differences in Hypoglycaemia-Related Hospital Admissions: A Case-Control Study in England’. Diabetes, Obesity and Metabolism. doi: 10.1111/dom.12941.
Zhang, Chun-Yu, Ai-Jun Sun, Shu-Ning Zhang, Chao-neng Wu, Ming-Qiang Fu, Guang Xia, Ke-Qiang Wang, Yun-Zeng Zou, and Jun-Bo Ge. 2010. ‘Effects of Intensive Glucose Control on Incidence of Cardiovascular Events in Patients with Type 2 Diabetes: A Meta-Analysis’. Annals of Medicine 42(4):305–15. doi: 10.3109/07853891003796752.
Zinman, Bernard, Christoph Wanner, John M. Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, and Silvio E. Inzucchi. 2015. ‘Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes’. New England Journal of Medicine 373(22):2117–28. doi: 10.1056/NEJMoa1504720.
Zoungas, Sophia, Hisatomi Arima, Hertzel C. Gerstein, Rury R. Holman, Mark Woodward, Peter Reaven, Rodney A. Hayward, Timothy Craven, Ruth L. Coleman, and John Chalmers. 2017. ‘Effects of Intensive Glucose Control on Microvascular Outcomes in Patients with Type 2 Diabetes: A Meta-Analysis of Individual Participant Data from Randomised Controlled Trials’. The Lancet Diabetes & Endocrinology 5(6):431–37. doi: 10.1016/S2213-8587(17)30104-3.